Recombinant follicle stimulating hormone is effective in poor responders to highly purified follicle stimulating hormone.
Open Access
- 1 January 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 15 (1) , 17-20
- https://doi.org/10.1093/humrep/15.1.17
Abstract
Ovarian stimulation in cases of poor ovarian responsiveness is an important challenge in in-vitro fertilization (IVF) programmes. Despite improvements in oocyte number and quality, an ideal ovarian stimulation strategy has yet to be defined. Here, the results of ovarian stimulation with recombinant follicle stimulating hormone (rFSH) in 28 poor responders to highly purified FSH (FSH-HP) with high basal concentrations of FSH are reported. The protocols used on the FSH-HP and rFSH cycles were identical with the sole exception of the FSH preparation: triptorelin 0.1 mg/day (gonadotrophin-releasing hormone, GnRH-agonist short protocol) and the starting FSH dose of 300 IU/day were administered from day 2 of the menstrual cycle. Ovarian outcome was classified as `normal', `intermediate' and `poor', depending on the number of mature oocytes retrieved and the peak serum oestradiol concentration. Nine of the 28 subjects had an intermediate ovarian response to re-stimulation with rFSH. In the 26 patients who received human chorionic gonadotrophin on both cycles, re-stimulation resulted in a significant increase (P < 0.05) in the mean number of mature oocytes (2.4 ± 1.4 versus 1.7 ± 0.8), mean peak oestradiol concentration (606 ± 252 versus 443 ± 32 pg/ml) and fertilization rate (73.0 versus 53.3%). Four pregnancies were achieved. It is concluded that rFSH in a GnRH-agonist short protocol improves the ovarian outcome in poor responders to FSH-HP with high basal concentrations of FSH.Keywords
This publication has 19 references indexed in Scilit:
- Cessation of Gonadotropin-Releasing Hormone Agonist Therapy Combined with High-Dose Gonadotropin Stimulation Yields Favorable Pregnancy Results in Low RespondersFertility and Sterility, 1998
- Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniquesHuman Reproduction, 1997
- In Vitro Fertilization with Low-Dose Clomiphene Citrate Stimulation in Women Who Respond Poorly to SuperovulationJournal of Assisted Reproduction and Genetics, 1997
- High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcomeFertility and Sterility, 1996
- Genetic engineering of human FSH (Gonal-F(R))Human Reproduction Update, 1996
- Adjuvant growth hormone therapy in poor responders to in-vitro fertilization: a prospective randomized placebo-controlled double-blind studyHuman Reproduction, 1995
- Follicle-Stimulating Hormone versus Human Menopausal Gonadotropin for in vitro Fertilization: Results of a Meta-AnalysisHormone Research, 1995
- Endocrinology: Exogenous follicle stimulating hormone ovarian reserve test (EFORT): a simple and reliable screening test for detecting ‘poor responders’ in in-vitro fertilizationHuman Reproduction, 1994
- The poor-responder patient in an in vitro fertilization-embryo transfer programJournal of Assisted Reproduction and Genetics, 1993
- Comparison of ‘poor’ responders with ‘good’ responders using a standard buserelin/human menopausal gonadotrophin regime for in-vitro fertilizationHuman Reproduction, 1991